What Feraheme Treats: Main Uses and Benefits

Feraheme is an intravenous iron replacement product which is commonly used for the treatment of Iron Deficiency Anemia (IDA) in adults. This treatment is relevant for managing symptoms related to systemic imbalance that stem from the iron deficiency.

This medication plays a role in managing IDA across several key scenarios: it is used for anemia associated with Chronic Kidney Disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients, and it is considered relevant when individuals have an unsatisfactory response to oral iron therapy or cannot tolerate associated oral treatments. By directly replenishing essential iron stores, the treatment supports the manufacturing of hemoglobin and red blood cells. The intravenous route supports patients by bypassing issues like poor oral iron absorption and may assist with iron deficiency.

---

Quick Fact: Relief for Iron Deficiency

Feraheme is commonly used to help manage symptoms related to systemic imbalance that accompany Iron Deficiency Anemia (IDA), offering supportive relief in clinical settings where oral iron is ineffective or cannot be tolerated.

Who can and cannot use Feraheme?

Eligibility for Feraheme (ferumoxytol) is determined by specific criteria and contraindications established in official regulatory documents.

Eligibility Scope

Classification	Who Can/Cannot Use Feraheme
Eligible Populations	Adult patients (18 years and older) with Iron Deficiency Anemia (IDA) who have either Chronic Kidney Disease (CKD) or who have documented intolerance to oral iron or an unsatisfactory response to oral iron therapy.
Contraindicated Populations	Patients with a known hypersensitivity to Feraheme or any of its components. Patients with a history of allergic reaction to any intravenous iron product. Patients with evidence of iron overload (such as hemochromatosis or hemosiderosis).
Use Not Established	Pediatric patients (under 18 years); safety and efficacy have not been established in this age group.

Important Restrictions

Use is restricted to adult patients whose anemia is confirmed to be caused by iron deficiency. For patients with multiple drug allergies, the potential risks and benefits must be carefully considered due to a heightened risk of hypersensitivity reactions. While no specific dosage adjustment is recommended for patients with kidney impairment, its use in patients with liver dysfunction requires careful clinical assessment. The administration during pregnancy or lactation is generally recommended only when the potential benefit outweighs the risk.

Contraindicated Combinations and Timing Rules

The regulatory label imposes restrictions concerning co-administration. Use of Feraheme is officially restricted for individuals who have experienced an allergic reaction to any intravenous iron product, reflecting a class-based contraindication. For co-administered agents that may cause serious hypersensitivity reactions or hypotension, such as certain chemotherapeutic agents or monoclonal antibodies, a mandatory 30-minute separation window must be observed between administrations. This rule addresses the potential for a combined pharmacodynamic effect, and elderly patients may have more severe outcomes from these reactions.

Drug and Substance Interactions

Feraheme is expected to reduce the absorption of oral iron preparations when co-administered. This interaction may decrease the systemic exposure of the oral iron product. The regulatory label documents no known interactions with food or drinks. Furthermore, no formal pharmacokinetic interactions involving CYP enzymes or drug transporters are documented in the prescribing information, as relevant studies were not conducted.

Interference with Diagnostic Procedures

Feraheme, due to its composition, is documented to interfere with specific medical testing. The drug can alter Magnetic Resonance Imaging (MRI) studies for up to three months following administration. Specifically, T2-weighted MR pulse sequences should not be performed earlier than four weeks after the last dose. Additionally, blood samples drawn within 24 hours of administration may lead to the overestimation of serum iron and transferrin bound iron values in laboratory assays.

Nanoparticle Delivery to Iron Storage Centers

The Feraheme complex is an iron nanoparticle coated in a carbohydrate shell, which is recognized and taken up by the reticuloendothelial system (RES), primarily by macrophages in the liver, spleen, and bone marrow. This targeted uptake results in iron delivery to the body's iron processing and storage cells.

Intracellular Processing and Controlled Iron Release

Once inside the macrophage, the carbohydrate coating is broken down by cellular enzymes in a controlled cascade, leading to the gradual release of iron from the core. This released iron enters the labile iron pool and is either stored as ferritin or exported into the blood, where it immediately binds to transferrin. This process involves the body's natural iron transport mechanisms.

Fueling Hemoglobin Synthesis

The iron delivered by transferrin is then transported to the bone marrow, where it is a critical substrate for the erythroid precursors (developing red blood cells). This mechanism provides the necessary molecular component for the synthesis of functional hemoglobin.

How to Use Feraheme: Official Administration Guidelines

Feraheme (Ferumoxytol) is a prescription medicine that must be administered only by a healthcare professional as a structured, short-term course delivered directly into the vein.

---

Administration Scope

Instruction Category	Official Guideline
Route of Administration	Exclusively by intravenous (IV) infusion.
Dosing Schedule	A complete treatment course consists of a total of 1020 mg elemental iron, divided into two doses of 510 mg each.
Timing in Relation to Meals	Not applicable; the route of administration is intravenous.
Preparation Requirements	Dilute each 510 mg dose in 50 to 200 mL of 0.9% Sodium Chloride Injection or 5% Dextrose Injection immediately prior to use.
Age-Group Administration Rules	The drug is for use in adult patients. General caution is advised for administration in geriatric patients.
Special Procedural Conditions	The infusion must be administered over a period of at least 15 minutes, while the patient is maintained in a reclined or semi-reclined position.

---

Instruction Classifications (High-level)

Classification	Description
Administration method type	Intravenous (IV) infusion only.
Frequency pattern	Short-term, two-dose course; the second dose is given between 3 and 8 days after the initial dose.
Use-context constraints	For patients receiving hemodialysis, administration should occur once blood pressure is stable and the patient has completed at least one hour of hemodialysis.

---

Resulting Procedural Structure

The full course involves two distinct administrations, with the patient's hematologic response (e.g., hemoglobin and ferritin) evaluated at least one month following the final dose. The full 1020 mg course may be readministered if the iron deficiency persists or recurs. Proper administration requires at least a 30 minute interval between Feraheme and certain other medications.

Research Evidence / Overview of Studies for Feraheme

Evidence for use in Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD)

Research focused on studying Iron Deficiency Anemia (IDA) in adult patients who also have Chronic Kidney Disease (CKD). The evidence is based on short-term Randomized Controlled Trials (RCTs) that included comparisons against a placebo or an active iron comparator. These trials monitored adult patients who were either on dialysis or who were non-dialysis dependent.

The studies examined outcomes related to systemic imbalance by measuring changes in hemoglobin (Hgb) levels and monitoring shifts in iron store biomarkers (ferritin and TSAT). Studies measured the changes in Hgb levels over the study period, typically assessed at five weeks. Research described the patterns of measured changes in iron storage parameters across the observed populations. However, the evidence is mostly short-term, and data on the patterns of subsequent iron intervention are not as fully established.

---

Evidence for use in General Iron Deficiency Anemia (IDA)

Research included the broader group of adult patients with IDA due to various causes, especially for those who experienced an unsatisfactory response to oral iron or who could not tolerate oral iron therapy. This evidence is derived from Phase 3 Randomized Controlled Trials (RCTs).

Trials examined outcomes such as Hgb change and the shifts in iron store biomarkers, and also explored patient-reported outcomes (PROs), such as scores related to fatigue. The findings described the measured changes in iron store biomarkers across these varied populations. Results apply only to the populations studied in the trials, as high-risk groups were often excluded.

---

Durability of Effect and Long-Term Follow-up

The primary studies observed responses over a short time interval, typically about five weeks. Longer observational extensions monitored patients for up to six to twelve months. These studies provided insight into the time between initial treatment and subsequent iron intervention. However, there is limited information for long-term health outcomes compared to the initial short-term physiological findings.

What is Still Being Characterized in the Evidence

Follow-up durations were limited in many core efficacy trials, meaning long-term effects on health outcomes are not fully established. Comparative evidence against all available intravenous iron treatments is lacking in some specific patient subgroups. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy (Trial NCT03657433)

The storage and disposal of Feraheme (ferumoxytol) must strictly follow official regulatory requirements to maintain product integrity.

Undiluted vials must be stored at controlled room temperature (20 C to 25 C or 68 F to 77 F) and must not be frozen.

For protection from light, the product should be stored in its original carton. As a prescription medicine, it must be kept out of the sight and reach of children.

Since the product is supplied in single-use vials and contains no preservatives, the solution should be used immediately after dilution. If needed, the diluted product is stable for up to 4 hours at room temperature or 48 hours under refrigeration.

Any unused portion remaining in the single-use vial must be discarded. Disposal of all expired or unused product and associated waste must be managed according to local pharmaceutical waste regulations.